Three Houston schools crack the top 10 high schools in Texas. Photo by Klaus Vedfelt/Getty Images

A couple of Texas schools have been working hard on extra credit, or so says the latest ranking by U.S. News & World Report. Its list of the Best U.S. High Schools, released April 21, includes two Dallas public schools in the national top 10, with several other Texas learning institutions popping up further down.

The School for the Talented and Gifted earns a coveted No. 6 spot, followed by Irma Lerma Rangel Young Women's Leadership School at No. 10. Last year's No. 12, Science and Engineering Magnet School, slips slightly to No. 17 this year. All three are in the Dallas ISD.

On a state level, this trio takes the top three spots. Houston's DeBakey High School for Health Professions is No. 4 in Texas, with Carnegie Vanguard High School at No. 6 and Eastwood Academy at No. 10.

This is the most expansive edition yet, with the consumer advice outlet evaluating more than 17,700 public high schools on how well they serve all of their students, regardless of economic or ethnic background.

The methodology focuses on six factors: college readiness, reading and math proficiency, reading and math performance, underserved student performance, college curriculum breadth, and graduation rates. College readiness measures participation and performance on AP and IB exams.

"The Best High Schools rankings provide the most comprehensive, data-based information on nearly every public high school in the country," says Anita Narayan, managing editor of education at U.S. News. "Families can use this information to see how their local schools compare on graduation rates and state assessments, as well as academic performance by students who are traditionally underserved — those who are black, Hispanic, or from low-income households."

Also appearing on the national list are six more Texas schools within the top 100:

  • No. 29, DeBakey High School for Health Professions, Houston ISD
  • No. 34, Liberal Arts and Science Academy, Austin ISD
  • No. 44, Carnegie Vanguard High School, Houston ISD
  • No. 61, Early College High School, Laredo ISD
  • No. 82, Young Women's Leadership Academy, Fort Worth ISD
  • No. 91 Basis San Antonio- Shavano Campus, Basis Texas Castle Hills

The report also shows that the highest-ranked schools are scattered throughout the country, showing that the best schools are not concentrated in any one geographic area. Nine different states are represented among the top 10 schools. More broadly, the top 100 schools span 29 states.

------

This article originally ran on CultureMap.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Axiom Space-tested cancer drug advances to clinical trials

mission critical

A cancer-fighting drug tested aboard several Axiom Space missions is moving forward to clinical trials.

Rebecsinib, which targets a cancer cloning and immune evasion gene, ADAR1, has received FDA approval to enter clinical trials under active Investigational New Drug (IND) status, according to a news release. The drug was tested aboard Axiom Mission 2 (Ax-2) and Axiom Mission 3 (Ax-3). It was developed by Aspera Biomedicine, led by Dr. Catriona Jamieson, director of the UC San Diego Sanford Stem Cell Institute (SSCI).

The San Diego-based Aspera team and Houston-based Axiom partnered to allow Rebecsinib to be tested in microgravity. Tumors have been shown to grow more rapidly in microgravity and even mimic how aggressive cancers can develop in patients.

“In terms of tumor growth, we see a doubling in growth of these little mini-tumors in just 10 days,” Jamieson explained in the release.

Rebecsinib took part in the patient-derived tumor organoid testing aboard the International Space Station. Similar testing is planned to continue on Axiom Station, the company's commercial space station that's currently under development.

Additionally, the drug will be tested aboard Ax-4 under its active IND status, which was targeted to launch June 25.

“We anticipate that this monumental mission will inform the expanded development of the first ADAR1 inhibitory cancer stem cell targeting drug for a broad array of cancers," Jamieson added.

According to Axiom, the milestone represents the potential for commercial space collaborations.

“We’re proud to work with Aspera Biomedicines and the UC San Diego Sanford Stem Cell Institute, as together we have achieved a historic milestone, and we’re even more excited for what’s to come,” Tejpaul Bhatia, the new CEO of Axiom Space, said in the release. “This is how we crack the code of the space economy – uniting public and private partners to turn microgravity into a launchpad for breakthroughs.”